PHATHOM PHARMACEUTICALS, INC. (PHAT) Gross Margin
- Gross margin · 12 months: Value 82.92%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 82.92% | Gross profit / revenue. Period ending 2026-06-30. $198.73M ÷ $239.66M × 100 ≈ 82.92% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 198.73M USD | Gross Profit |
| Revenue | 239.66M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $198.73M | $239.66M | (m) | 82.92% |
| 2026-03-31 | $174.02M | $204.89M | (m) | 84.93% |
| 2025-12-31 | $152.51M | $175.11M | (m) | 87.09% |
| 2025-09-30 | $128.42M | $147.19M | (m) | 87.25% |
| 2025-06-30 | $99.11M | $114.04M | (m) | 86.91% |
| 2025-03-31 | $70.59M | $81.86M | (m) | 86.23% |
| 2024-12-31 | $47.28M | $55.25M | (m) | 85.57% |
| 2024-09-30 | $21.95M | $26.27M | (m) | 83.54% |
| 2024-06-30 | $7.95M | $9.92M | (m) | 80.15% |
| 2024-03-31 | $2.00M | $2.59M | (m) | 77.14% |
| 2023-12-31 | $515.00K | $682.00K | (m) | 75.51% |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |